A life-extending prostate cancer drug will continue to only be available to sufferers who have already undergone chemotherapy, the NHS financial watchdog said.
In final draft guidance reassessing the use in the NHS in England of abiraterone, the National Institute for Health and Care Excellence (Nice) ruled that to extend the availability of the drug was "not cost effective at its current price."
There is "clear evidence" that the use of abiraterone before chemotherapy gives patients "longer healthier lives," according to The Institute of Cancer Research, where the drug was discovered.
Nice's chief executive Sir Andrew Dillion said: "We know how important it is for patient to have the option to delay chemotherapy and its associated side affects, so we are disappointed not to be able to recommend abiraterone for use in this way.
"However, the manufacturer's own economic model demonstrated that the drug does not offer enough benefit to justify its price."
More top news
Banking giant Barclays has posted a 10% rise in annual pre-tax profits to £3.54 billion, up from £3.23 billion in 2016
Mobile phone users in the UK receive more than 33,000 messages and alerts a year, new research shows.
Theresa May is set to host crunch Brexit talks at Chequers as she bids to unite her Cabinet over Britain's plans for exiting the EU.